INTRODUCTION
============

*Helicobacter pylori* is the most common chronic bacterial infection in humans and is related to various gastrointestinal diseases such as gastritis, peptic ulcer, gastric cancer, and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue.[@b1-gnl-13-628],[@b2-gnl-13-628] The extraintestinal linking of *H. pylori* to various conditions, including hematologic, cardiovascular, metabolic, neurologic, and dermatologic disorders, has been investigated and recently published; the Maastricht V/Florence Consensus Report recommends eradication for patients who have iron deficiency anemia, idiopathic thrombocytopenic purpura, and vitamin B12 deficiency, although it is a weak grade recommendation.[@b3-gnl-13-628]--[@b5-gnl-13-628]

Patients with chronic kidney disease (CKD) often complain of dyspepsia due to various causes, and *H. pylori* infection should now be excluded for the diagnosis of functional dyspepsia.[@b3-gnl-13-628] However, epidemiologic studies have shown inconsistent results about the association between *H. pylori* infection and CKD.[@b6-gnl-13-628],[@b7-gnl-13-628] The increased interest in the relationship between *H. pylori* infection and CKD is due to extraintestinal associations such as insulin resistance or metabolic syndrome associated with *H. pylori* infection, which is expected to be highly relevant because diabetes and hypertension are the most common causes of CKD.[@b5-gnl-13-628],[@b8-gnl-13-628]

Three meta-analyses have been conducted for the association of *H. pylori* infection and CKD.[@b6-gnl-13-628],[@b7-gnl-13-628],[@b9-gnl-13-628] Wijarnpreecha *et al*.[@b7-gnl-13-628] found no significant association between non-dialysis-dependent CKD and *H. pylori* infection. Gu *et al*.[@b6-gnl-13-628] also revealed no evidence of association between dialysis-dependent CKD and *H. pylori* infection. Although these studies commonly claim no association, many articles were omitted during the literature search, and since both meta-analyses included only a subgroup (Wijarnpreecha *et al*. only included non-dialysis-dependent CKD, and Gu *et al*. only included dialysis-dependent CKD), an integrated analysis and subsequent sensitivity and subgroup analyses confirming the main result are needed. Another meta-analysis by Wijarnpreecha *et al*.[@b9-gnl-13-628] found no association between end-stage renal disease (ESRD) and *H. pylori* infection. However, this meta-analysis included several studies with pediatric patients and also many articles were omitted during the literature search. Moreover, the method of dialysis (hemodialysis or peritoneal dialysis), ethnicity of the enrolled population, and methodological quality of the included studies were not considered as confounding factors in the previous meta-analyses ([Table 1](#t1-gnl-13-628){ref-type="table"}). Therefore, this study aimed to evaluate the prevalence of *H. pylori* infection in patients with CKD with systematic review, meta-analysis, and meta-regression.

MATERIALS AND METHODS
=====================

This systematic review and meta-analysis fully adhered to the principles of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist ([Supplementary Table 1](#s1-gnl-13-628){ref-type="supplementary-material"}).[@b10-gnl-13-628]

1. Literature searching strategy
--------------------------------

MEDLINE (through PubMed), the Cochrane library, and Embase were searched using common keywords associated with *H. pylori* infection or CKD (from inception to April 2018) by two independent evaluators (C.S.B. and S.P.S.). Medical Subject Heading (MeSH) or Emtree keywords were selected for searching electronic databases. The abstracts of all identified studies were reviewed to exclude irrelevant articles. Full-text reviews were performed to determine whether the inclusion criteria were satisfied in the remaining studies, and the bibliographies of relevant articles were rigorously reviewed to identify additional studies. Disagreements between the evaluators were resolved by discussion. The detailed searching strategy is described in [Supplementary Table 2](#s1-gnl-13-628){ref-type="supplementary-material"}.

2. Selection criteria
---------------------

We included studies that met the following criteria: (1) studies designed to evaluate the prevalence of *H. pylori* infection in patients with CKD (vs. a control group without kidney diseases); (2) studies of human subjects; and (3) full-text publications. Studies that met the all of the inclusion criteria were sought and selected. The exclusion criteria were as follows: (1) publications with incomplete data; (2) review articles; (3) pediatric studies; (4) letters or case articles; (5) abstract-only publications; and (6) studies with CKD including DM nephropathy or renal transplant recipient (meta-analysis with DM nephropathy or renal transplant recipient is different topic of interest and already published[@b11-gnl-13-628],[@b12-gnl-13-628]). Studies meeting at least one of the exclusion criteria were excluded from this analysis.

3. Methodological quality
-------------------------

The methodological quality of the included publications was assessed using the Risk of Bias Assessment tool for Nonrandomized Studies (RoBANS).[@b13-gnl-13-628] The RoBANS tool contains six domains, including the selection of participants, confounding variables, measurement of intervention (exposure), blinding of outcome assessment, incomplete outcome data, and selective outcome reporting.[@b13-gnl-13-628] RoBANS is a validated tool that is reliable and feasible for the assessment of the methodological quality of nonrandomized studies. Review Manager version 5.3.3 (RevMan for Windows 7; the Nordic Cochrane Centre, Copenhagen, Denmark) was used to generate the summary of RoBANS results. Studies with matched participants (e.g., age or sex) and the diagnosis of *H. pylori* infection with two or more methods were ranked with low risk of bias in the selection of participants and incomplete outcome date variable, respectively. Two of the evaluators (C.S.B. and S.P.S.) independently assessed the methodological quality of all included studies, and any disagreements between the evaluators were resolved by discussion or consultation with a third evaluator (G.H.B.).

4. Primary and modifier-based analysis
--------------------------------------

Two evaluators (C.S.B. and S.P.S.) independently used the same data fill-in form to collect the primary summary outcome and modifiers in each study. The outcome was the prevalence of *H. pylori* infection in patients with CKD and the control groups. These ratios were extracted and evaluated using odds ratios (ORs). Sensitivity analyses, including cumulative and one-study-removed analyses, were performed to confirm the robustness of the main analysis results. These analyses were calculated in the order of publication year or effect size to find whether the time trend exists or which study is more or less influential in the pooled estimate and to find the small-study effect (to ensure no changes in the effect size if more small-effect size studies were added). We also performed subgroup and meta-regression analyses to identify the source of heterogeneity based on the multiple modifiers identified during the systematic review. These modifiers include the ethnicity of the study population, classification of CKD (ESRD on dialysis vs CKD not on dialysis), dialysis method among ESRD population (hemodialysis or not), duration of dialysis (more than 4 years or not) and methodological quality.

5. Statistical analysis
-----------------------

Comprehensive Meta-Analysis software version 3 (Borenstein M, Hedges L, Higgins J and Rothstein H; Biostat, Englewood, NJ, USA) was used for this meta-analysis. We calculated the ORs with 95% confidence intervals (CIs) using 2×2 tables from the original articles to compare the prevalence of *H. pylori* infection between the patients with CKD and the control group whenever possible. Heterogeneity was determined using the I^2^ test developed by Higgins, which measures the percentage of total variation across studies.[@b14-gnl-13-628] I^2^ was calculated as follows: I^2^ (%)=100×(Q-df)/Q, where Q is Cochrane's heterogeneity statistic and df signifies the degrees of freedom. Negative values for I^2^ were set to zero, and an I^2^ value over 50% was considered to be of substantial heterogeneity (range, 0% to 100%).[@b15-gnl-13-628] Pooled-effect sizes with 95% CIs were calculated using a random effects model and the method of DerSimonian and Laird due to methodological heterogeneity.[@b16-gnl-13-628] These results were confirmed by the I^2^ test. Significance was set at p=0.05. Publication bias was evaluated using Begg's funnel plot, Egger's test of the intercept, Begg and Mazumdar's rank correlation test, and Duval and Tweedie's trim and fill method.[@b17-gnl-13-628]--[@b21-gnl-13-628]

RESULTS
=======

1. Identification of relevant studies
-------------------------------------

[Fig. 1](#f1-gnl-13-628){ref-type="fig"} presents a flow diagram showing how relevant studies were identified. In total, 1,296 articles were identified by a search of three databases. In all, 347 were duplicate studies, and an additional 732 studies were excluded during the initial screening through a review of titles and abstracts. The full texts of the remaining 219 studies were then thoroughly reviewed. Among these studies, 171 articles were excluded from the final analysis. The reasons for study exclusion during the final review were as follows: narrative review article (n=7), meta-analysis or systematic review (n=5), letters, comment, editorial or reply to questions (n=15), abstract-only article (n=4), case study (n=5), duplicated data (n=1), and incomplete data (n=134). Forty-eight studies[@b22-gnl-13-628]--[@b69-gnl-13-628] were included in the systematic review; however, study by Kong *et al*.[@b40-gnl-13-628] showed no crude rate of *H. pylori* infection, therefore, this was excluded in the final meta-analysis. The remaining 47 studies[@b22-gnl-13-628]--[@b39-gnl-13-628],[@b41-gnl-13-628]--[@b69-gnl-13-628] were included in the final quantitative analysis.

2. Characteristics of included studies
--------------------------------------

In the 47 case-control or cross-sectional studies, we identified a total of 4,084 patients with CKD (2,470 patients on dialysis and 1,916 patients on hemodialysis) and 6,908 controls without CKD. The total prevalence of *H. pylori* infection in patients with CKD was 48.2% (1,968/4,084), and it was 59.3% (4,097/6,908) in the control group. The included studies were published between 1989 and 2017. Only one study included an African population,[@b22-gnl-13-628] whereas the remaining studies included Asian (17 studies),[@b23-gnl-13-628]--[@b39-gnl-13-628] Western (16 studies),[@b41-gnl-13-628]--[@b56-gnl-13-628] Middle Eastern (11 studies),[@b57-gnl-13-628]--[@b67-gnl-13-628] and South American populations (two studies).[@b68-gnl-13-628],[@b69-gnl-13-628] Most articles were written in English, except for two Spanish,[@b68-gnl-13-628],[@b69-gnl-13-628] one Japanese,[@b23-gnl-13-628] one Korean,[@b27-gnl-13-628] one Czech,[@b51-gnl-13-628] and one Turkish[@b59-gnl-13-628] studies. The age of the enrolled population ranged from 32.5±5.3 to 69.5±13.8 years (mean±standard deviation). The diagnostic method of *H. pylori* infection varied according to each study, and included histology (Warthin-Starry, H&E, Giemsa, alcian blue-periodic acid Schiff's, Loeffler's methylene blue stain), culture, serology (IgG antibody against *H. pylori*), urease testing, phase-contrast microscopy, analysis for the stool antigen for *H. pylori*, and a urea breath test. The duration of dialysis in the enrolled population ranged from at least 6 months to 8.4±0.3 years (mean±standard deviation). Most studies presented a crude rate of *H. pylori* infection in patients with CKD versus a control group, and two studies[@b37-gnl-13-628],[@b40-gnl-13-628] presented adjusted ORs, which were adjusted for age, sex, peptic ulcer history, steroid or medication use, diabetes, hypertension, chronic heart failure, coronary artery disease, and liver cirrhosis in Chang and Hu[@b37-gnl-13-628] and for sex, age, hypertension, diabetes, body mass index, uric acid, smoking, drinking, total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol in Kong *et al*.[@b40-gnl-13-628] The clinical characteristics of the included studies are shown in [Table 2](#t2-gnl-13-628){ref-type="table"} (study by Kong *et al*. is described in the [Table 2](#t2-gnl-13-628){ref-type="table"}, but was not included in the final meta-analysis).

3. Prevalence of *H. pylori* infection in patients with CKD
-----------------------------------------------------------

The pooled meta-analysis of 34 studies exhibited a significantly lower prevalence of *H. pylori* infection in patients with CKD (vs a control group) (OR, 0.64; 95% CI, 0.52 to 0.79; I^2^=79.53%) in a random effect model analysis ([Fig. 2](#f2-gnl-13-628){ref-type="fig"}).

4. Sensitivity meta-analysis
----------------------------

A cumulative meta-analysis of the included studies based on publication year showed no specific trend over time ([Supplementary Fig. 1A](#s1-gnl-13-628){ref-type="supplementary-material"}). A cumulative meta-analysis based on effect size showed no small study bias ([Supplementary Fig. 1B](#s1-gnl-13-628){ref-type="supplementary-material"}). A one-study-removed meta-analysis revealed a stable feature ([Supplementary Fig. 1C](#s1-gnl-13-628){ref-type="supplementary-material"}). Overall, the sensitivity meta-analyses revealed robust results.

5. Subgroup analyses according to the modifiers
-----------------------------------------------

The ESRD on dialysis subgroup showed robust lower prevalence of *H. pylori* (vs a control group) (OR, 0.58; 95% CI, 0.51 to 0.66) ([Supplementary Fig. 2A](#s1-gnl-13-628){ref-type="supplementary-material"}). The hemodialysis subgroup also showed lower prevalence of *H. pylori* (OR, 0.60; 95% CI, 0.52 to 0.69) ([Supplementary Fig. 2B](#s1-gnl-13-628){ref-type="supplementary-material"}). This effect was intensified in a subgroup of hemodialysis for more than 4 years (OR, 0.34; 95% CI, 0.27 to 0.43) ([Supplementary Fig. 2C](#s1-gnl-13-628){ref-type="supplementary-material"}).

However, analysis of the ethnicity of the enrolled population showed a different result. Asian (OR, 0.46; 95% CI, 0.41 to 0.52) and Western population (OR, 0.78; 95% CI, 0.66 to 0.92) showed a lower prevalence; the African (OR, 0.90; 95% CI, 0.48 to 1.70), Middle Eastern (OR, 1.1; 95% CI, 0.87 to 1.34), and South American populations (OR, 0.76; 95% CI, 0.46 to 1.27) showed no significant difference of *H. pylori* infection in patients with CKD (vs a control group) ([Supplementary Fig. 2D](#s1-gnl-13-628){ref-type="supplementary-material"}).

In terms of the methodological quality of the included studies, high-quality studies (defined as having no negative component in the RoBANS evaluation) showed a significantly lower prevalence of *H. pylori* infection in patients with CKD (OR, 0.57; 95% CI, 0.49 to 0.67). However, low-quality studies (defined as having any negative component in the RoBANS evaluation) showed no significant difference (OR, 0.66; 95% CI, 0.59 to 0.73) ([Supplementary Fig. 2E](#s1-gnl-13-628){ref-type="supplementary-material"}). The detailed quality evaluation is described in [Fig. 3](#f3-gnl-13-628){ref-type="fig"}.

6. Meta-regression analyses
---------------------------

Among the potential confounding factors, including whether the population was on dialysis or not, ethnicity, dialysis method, dialysis duration (more than 4 years), and methodological quality, there were no covariates that explained heterogeneity in the meta-regression tests ([Table 3](#t3-gnl-13-628){ref-type="table"}).

7. Analysis of publication bias
-------------------------------

A funnel plot for the included studies is illustrated in [Fig. 4](#f4-gnl-13-628){ref-type="fig"} and shows a symmetrical shape. Egger's regression test revealed that the intercept was 0.23 (95% CI, −1.23 to 1.68; t-value, 0.31; df=45, p=0.38 \[1-tailed\] and p=0.76 \[2-tailed\]). A trim and fill analysis showed that no study was missed or trimmed. The rank correlation test showed Kendall's tau was −0.04 with a continuity correction (p=0.33 \[1-tailed\] and p=0.66 \[2-tailed\]). Overall, there was no evidence of publication bias in this meta-analysis.

DISCUSSION
==========

This meta-analysis confirmed the lower prevalence of *H. pylori* infection in patients with CKD (The total prevalence of *H. pylori* infection was 48.2% in patients with CKD vs 59.3% in the control group). Although the previous three meta-analyses claimed no significant association, the current study is the first meta-analysis representing the real prevalence because many articles were omitted during systematic review process in the previous systematic review (47 studies were included in the current study, whereas Wijarnpreecha *et al*.[@b7-gnl-13-628] included nine studies, Gu *et al*.[@b6-gnl-13-628] included 15 studies, and Wijarnpreecha *et al*.[@b9-gnl-13-628] included 37 studies), and these studies enrolled a subgroup of patients with CKD according to whether patients were on dialysis or not. Many articles were omitted in these systematic reviews because searching strategy was unclear.[@b6-gnl-13-628],[@b7-gnl-13-628],[@b9-gnl-13-628] Studies with renal transplant recipients or diabetic nephropathy, and pediatric population was included in the meta-analysis because inclusion criteria was vague ([Table 1](#t1-gnl-13-628){ref-type="table"}).[@b9-gnl-13-628]

Although most subgroup analyses verified according to the modifiers in the current study showed consistent results with main outcome, the ethnicity of the study population showed inconsistent results. Analyses with an Asian and Western population showed a significant lower prevalence and analyses of African, Middle Eastern, and South American populations commonly showed no significant difference. Considering most studies with an African, Middle Eastern, and South American population were included in the low-quality methodology group, these inconsistencies indicate and favor a significant lower prevalence of *H. pylori* infection in patients with CKD.

The most important factor for the determination of the methodological quality was an incomplete outcome of each study, especially the method of diagnosing *H. pylori* infection ([Fig. 3](#f3-gnl-13-628){ref-type="fig"}). Included studies used various methods, including a urease test, histology, culture, a urea breath test, serology, or a stool antigen test. Although the urease test, histology, urea breath test, and stool antigen test have a high diagnostic value, with sensitivity and specificity exceeding 90% for the determination of *H. pylori* infection status, each diagnostic method has some considerations.[@b3-gnl-13-628],[@b70-gnl-13-628],[@b71-gnl-13-628] False-negative results in the urease test, histology, urea breath test, and stool antigen test can be detected when patients are taking antibiotics, proton pump inhibitors, or bismuth, which are frequently prescribed drugs in patients with CKD.[@b3-gnl-13-628],[@b71-gnl-13-628],[@b72-gnl-13-628] Therefore, the Maastricht V/Florence Consensus Report recommends that proton pump inhibitors should be discontinued at least 2 weeks before testing, and antibiotics and bismuth should be discontinued at least 4 weeks before testing.[@b3-gnl-13-628] The serology test, which detects an IgG antibody against *H. pylori*, needs local validation before clinical application, and its overall sensitivity and specificity from published studies was less than 90%, which shows lower diagnostic value than the other tests.[@b73-gnl-13-628] The diagnostic value of histology is higher than the other tests, but it is dependent on where the biopsies were conducted and how many specimens were obtained. The degree of atrophic gastritis or intestinal metaplasia is also important for obtaining biopsy tissue for histology, influencing the accurate determination of *H. pylori* infection status.[@b3-gnl-13-628] In the previous meta-analysis, subgroup analysis revealed a trend of decreased risk of *H. pylori* infection in patients with CKD that was diagnosed with histology, excluding other diagnostic methods, and it had a marked decrease in heterogeneity between studies.[@b7-gnl-13-628] This indicates that the diagnostic values of all currently available methods are not perfect and are only valid and accurate in certain situations. Taking into account all of the above considerations, only a single diagnostic method is insufficient, and combining diagnostic methods is expected to have a high diagnostic yield. Therefore, studies combining diagnostic methods were included in the low-risk group, and studies with single diagnostic method were included in the high-risk group of the incomplete outcome category of RoBANS in the current study.

Although the pathogenesis of a lower prevalence of *H. pylori* infection in patients with CKD is not completely understood, several hypotheses have been proposed to explain the mechanism. First, frequent use of antacids or antibiotics in patients with CKD might be associated with decreased prevalence.[@b46-gnl-13-628] The subgroup analysis of the current study showed that the subgroup with a dialysis duration of more than 4 years showed a more intensified lower prevalence (OR, 0.34; 95% CI, 0.27 to 0.43), and a previous meta-analysis also showed a consistent result, indicating frequent antacid or antibiotic consumption might be associated with this finding.[@b6-gnl-13-628] Second, high blood urea nitrogen level was suspected as the cause of inhibited growth of *H. pylori*.[@b45-gnl-13-628] However, this was not consistent in other studies.[@b44-gnl-13-628],[@b74-gnl-13-628] Lastly, increased inflammatory cytokines in patients with CKD leads to gastric mucosal damage, which in turn makes it difficult for *H. pylori* to survive.[@b7-gnl-13-628],[@b75-gnl-13-628]

This meta-analysis included the largest number of articles identified by a comprehensive literature search, and potential confounding modifiers were searched within each study whenever possible. Sensitivity analyses, subgroup analyses, and meta-regression tests were performed to demonstrate robustness or to identify the reason of heterogeneity. Despite the strengths, several limitations were detected during the systematic review. First, only two studies presented adjusted outcomes.[@b37-gnl-13-628],[@b40-gnl-13-628] These two studies presented different associations between *H. pylori* infection and CKD (CKD vs control: OR, 0.64; 95% CI, 0.51 to 0.81 in Chang *et al*. vs OR, 0.92; 95% CI, 0.75 to 1.12 in Kong *et al*.). Considering the high methodological quality of Chang *et al*., the inverse association is consistent with the main result of current study, but more studies with adjusted variables are needed to explain this inconsistent result. Second, only case-control or cross-sectional studies were found during systematic review of this topic. Because the overall quality of the evidence is influenced by individual studies, future addition of high-quality studies would enhance the level of evidence. Third, it is not possible to determine the causality of the interaction-whether *H. pylori* influences the progression of kidney disease or CKD influences the *H. pylori* prevalence.

In conclusion, the results of this study suggest that there is a lower prevalence of *H. pylori* infection in patients with CKD.
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![Prevalence of *Helicobacter pylori* infection in patients with CKD (vs control group). The size of each square is proportional to the study's weight. Diamond is the summary estimate from the pooled studies (random-effects model). Heterogeneity: χ^2^=224.693, df=46 (p\<0.001), I^2^=79.582%. Test for overall effect: Z=−4.172 (p\<0.001).\
CKD, chronic kidney disease; CI, confidence interval.](gnl-13-628f2){#f2-gnl-13-628}

![Risk of Bias Assessment tool for Nonrandomized Studies (RoBANS) for the assessment of methodological quality for all included studies. (+) Denotes low risk of bias, blank denotes unclear risk of bias, (−) denotes high risk of bias.](gnl-13-628f3){#f3-gnl-13-628}

![Funnel plot of included studies. The line in the center is the natural logarithm of the pooled odds ratio (OR), and the two oblique lines are pseudo 95% confidence limits.](gnl-13-628f4){#f4-gnl-13-628}

###### 

Comparison of Previous Meta-Analyses with the Current Analysis

  Parameters                                                                        Current study                                                                                                             Gu *et al*.[@b6-gnl-13-628]                                                                                                                            Wijarnpreecha *et al*.[@b7-gnl-13-628]                                                                                                           Wijarnpreecha *et al*.[@b9-gnl-13-628]
  --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------
  No. of included studies                                                           47 Studies in systematic review (46 studies for meta-analysis)                                                            15 Studies                                                                                                                                             9 Studies                                                                                                                                        37 Studies in systematic review (35 studies for meta-analysis)
  Main outcome                                                                      Lower prevalence of *H. pylori* infection in patients with CKD compared to control group (OR, 0.64; 95% CI, 0.52--0.79)   No significant difference in the prevalence of *H. pylori* infection between patients with dialysis and control group (OR, 0.86; 95% CI, 0.52--1.42)   No significant difference in the prevalence of *H. pylori* infection between patients with CKD and control group (OR, 1.2; 95% CI, 0.73--1.97)   No significant difference in the prevalence of *H. pylori* infection between patients with ESRD and control group (RR, 0.77; 95% CI, 0.59--1.00)
  Whether dialysis patients were included or not                                    Included dialysis patients (ESRD) and non-dialysis patients with CKD                                                      Only patients with dialysis-dependent CKD (ESRD)                                                                                                       Only patients with non-dialysis-dependent CKD                                                                                                    Only patients with ESRD
  Whether pediatric patients were included or not                                   Excluded                                                                                                                  Included                                                                                                                                               Excluded                                                                                                                                         Included
  Whether diabetic nephropathy or renal transplant recipient were included or not   Excluded                                                                                                                  Included                                                                                                                                               Included                                                                                                                                         Included
  Whether analysis based on modifiers were included or not (meta-regression)        Included                                                                                                                  Not included                                                                                                                                           Not included                                                                                                                                     Not included

*H. pylori*, *Helicobacter pylori*; CKD, chronic kidney disease; OR, odds ratio; CI, confidence interval; ESRD, end-stage renal disease; RR, risk ratio.

###### 

Clinical Data of Included Studies on the Prevalence of *H. pylori* Infection in Patients with CKD (vs Control Group)

  Study                                                            Nationality    Age, mean±SD, yr                                                                                                                                                                                                             Study format                                 *H. pylori* test                                                                      Duration of dialysis, mean±SD, mo                                      CKD (infected/total)                                                                                                                                                     Control (infected/total)
  ---------------------------------------------------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------
  Offerhaus *et al*. (1989)[@b41-gnl-13-628]                       Netherland     ESRD: 52 (24--78), control: 47 (39--61)                                                                                                                                                                                      Case-control                                 IgG antibody against *H. pylori*                                                      NS                                                                     22/50 (ESRD)                                                                                                                                                             18/40
  Shousha *et al*. (1990)[@b42-gnl-13-628]                         UK             ESRD: 49.7±14.3 (26--78), control: 52.6±18.5 (20--84)                                                                                                                                                                        Case-control                                 Warthin-Starry, Giemsa                                                                NS                                                                     12/50 (ESRD)                                                                                                                                                             51/120
  Davenport *et al*. (1991)[@b43-gnl-13-628]                       UK             HD: median 54 (22--75) (age-matched control)                                                                                                                                                                                 Case-control                                 IgG antibody against *H. pylori*                                                      Median 38 (1--76)                                                      27/76 (HD)                                                                                                                                                               74/247
  Loffeld *et al*. (1991)[@b44-gnl-13-628]                         Netherlands    HD: 58 (20--82) (age-matched control)                                                                                                                                                                                        Case-control                                 IgG antibody against *H. pylori*                                                      Median 4.2 yr (2--16 yr)                                               13/30 (HD)                                                                                                                                                               230/500
  Nieves *et al*. (1992)[@b68-gnl-13-628]                          Venezuela      ESRD: 39±16 (18--72), control: 36±17 (17--74)                                                                                                                                                                                Case-control                                 H&E, Giemsa                                                                           NS                                                                     15/26 (ESRD)                                                                                                                                                             12/26
  Gladziwa *et al*. (1993)[@b45-gnl-13-628]                        Germany        HD: 55.1±12.0, CKD without dialysis: 61.2±13.8, control: 53.8±13.2                                                                                                                                                           Case-control                                 Urease test, Warthin-Starry, culture, phase-contrast microscopy                       43.8±47.2 (5--200)                                                     21/45 (CKD with or without dialysis)                                                                                                                                     45/83
  Tokushima (1995)[@b23-gnl-13-628]                                Japan          ESRD: 57.1±1.54, control: 53.6±1.41                                                                                                                                                                                          Case-control                                 H&E, culture                                                                          33.8±4.56                                                              23/43 (dialysis)                                                                                                                                                         21/34
  Jaspersen *et al*. (1995)[@b46-gnl-13-628]                       Germany        HD: 54.6±11.8, control: 58.2±12.6                                                                                                                                                                                            Case-control                                 Urease test, modified Giemsa                                                          NS                                                                     7/34 (HD)                                                                                                                                                                47/127
  De Vecchi *et al*. (1995)[@b47-gnl-13-628]                       Italy          HD: median 49 (26--69), PD: median 36 (21--84)                                                                                                                                                                               Case-control                                 IgG antibody against *H. pylori*                                                      NS                                                                     37/67 (ESRD)                                                                                                                                                             51/67
  Krawczyk *et al*. (1996)[@b48-gnl-13-628]                        Poland         HD: 36.8±13.2 (21--55), control: 34.8±12.1 (age-matched control)                                                                                                                                                             Case-control                                 Urease test, modified Giemsa                                                          28±12.2                                                                13/21 (HD)                                                                                                                                                               14/22
  Abu Farsakh *et al*. (1996)[@b57-gnl-13-628]                     Jordan         HD: 40.3 (21--60), control: 39.4                                                                                                                                                                                             Case-control                                 H&E or culture                                                                        18 (2 wk to 108 mo)                                                    45/92 (HD)                                                                                                                                                               73/100
  Seyrek *et al*. (1996)[@b58-gnl-13-628]                          Turkey         HD: 41.4±1.4 (16--70) (age-matched control)                                                                                                                                                                                  Case-control                                 IgG antibody against *H. pylori*                                                      22.9±2.2 (6--120)                                                      13/91 (HD)                                                                                                                                                               8/35
  Luzza *et al*. (1996)[@b49-gnl-13-628]                           Italy          HD: 60±13 (age, sex matched control)                                                                                                                                                                                         Case-control                                 IgG antibody against *H. pylori*                                                      Median 46 (mean, 74±63)                                                75/103 (HD)                                                                                                                                                              80/103
  Vardar *et al*. (1997)[@b59-gnl-13-628]                          Turkey         CKD: 55±10.08, HD: 45.65±14.09, control: 48.47±13.78                                                                                                                                                                         Case-control                                 IgG antibody against *H. pylori*, urease test, histology                              NS                                                                     27/40                                                                                                                                                                    29/40
  Ozgür *et al*. (1997)[@b60-gnl-13-628]                           Turkey         HD: 37.27±14.08, control: 40.51±13.60                                                                                                                                                                                        Case-control                                 Urease test                                                                           28.87±28.92                                                            28/47 (HD)                                                                                                                                                               64/100
  Gür *et al*. (1999)[@b61-gnl-13-628]                             Turkey         Infected: 32.50±5.30, non-infected: 35.10±4.20                                                                                                                                                                               Case-control                                 Urease test, histology                                                                Infected: 21.80±11.64, non-infected: 21.20±16.40                       25/45 (HD)                                                                                                                                                               24/44
  Araki *et al*. (1999)[@b24-gnl-13-628]                           Japan          ESRD: 57.4±12.8 (33--87), control: 57.8±17.3 (20--88) (age, sex-matched control)                                                                                                                                             Case-control                                 H&E, culture, IgG antibody against *H. pylori*                                        7.6±5.2 yr                                                             29/63 (ESRD)                                                                                                                                                             42/64
  Yildiz *et al*. (1999)[@b62-gnl-13-628]                          Turkey         HD: 36.6±15.2 (18--83), control: 33.4±9.6 (21--58)                                                                                                                                                                           Cross-sectional                              IgG antibody against *H. pylori*                                                      32.5±27.7 (1--100)                                                     31/47 (HD)                                                                                                                                                               39/55
  Tamura *et al*. (1999)[@b25-gnl-13-628]                          Japan          ESRD: 52.2±1.8, control: 48.6±1.6                                                                                                                                                                                            Case-control                                 Urease test, histology, culture                                                       29.3±5.4                                                               25/49 (ESRD)                                                                                                                                                             26/48
  Fabrizi *et al*. (1999)[@b50-gnl-13-628]                         US             HD: 61.8±13.8, control: 58.9±13.9 (sex, race-matched control)                                                                                                                                                                Case-control                                 RIBATM *H. pylori* strip immunoblot assay                                             Median 29 (6--331)                                                     127/228 (HD)                                                                                                                                                             84/158
  Misra *et al*. (1999)[@b26-gnl-13-628]                           India          CKD: 35.4±14.6 (18--65), control: 33.33±13.9 (14--70)                                                                                                                                                                        Case-control                                 Urease test, histology                                                                NS                                                                     28/50 (CKD with or without dialysis)                                                                                                                                     39/50
  Karari *et al*. (2000)[@b22-gnl-13-628]                          Kenya          CKD: 38.70±14.16 (18--70), control: 41.90±14.95 (18--87) (age, sex-matched control)                                                                                                                                          Prospective study                            Urease test, histology                                                                NS                                                                     41/77 (CKD with or without dialysis)                                                                                                                                     43/77
  Kim *et al*. (2000)[@b27-gnl-13-628]                             Korea          ESRD: 41±2, control: 46±2 (age-matched control)                                                                                                                                                                              Case-control                                 Urease test, histology, culture                                                       NS                                                                     19/49 (CKD with or without dialysis)                                                                                                                                     29/41
  Wang *et al*. (2001)[@b28-gnl-13-628]                            Taiwan         HD: median 53.7 (20--66), control: median 50.4 (25--68)                                                                                                                                                                      Case-control                                 Histology, culture, IgG antibody against *H. pylori*, stool antigen for *H. pylori*   NS                                                                     40/80 (HD)                                                                                                                                                               48/60
  Cekin *et al*. (2002)[@b63-gnl-13-628]                           Turkey         ESRD: 39±13, control: 41±11 (age, sex-matched control)                                                                                                                                                                       Case-control                                 Urease test, histology (H&E, modified Giemsa)                                         NS                                                                     16/42 (ESRD)                                                                                                                                                             31/46
  Závada *et al*. (2002)[@b51-gnl-13-628]                          Czech          NS                                                                                                                                                                                                                           Case-control                                 Urease test, histology                                                                NS                                                                     4/37 (CKD)                                                                                                                                                               6/22
  Tsukada *et al*. (2002)[@b29-gnl-13-628]                         Japan          HD: 62.1±2.9, control: 55.4±3.0                                                                                                                                                                                              Case-control                                 Giemsa stain, urea breath test                                                        NS                                                                     14/47 (HD)                                                                                                                                                               31/55
  Olmos *et al*. (2003)[@b69-gnl-13-628]                           Argentina      ESRD: 57.5±17.2 (matched control)                                                                                                                                                                                            Case-control                                 IgG antibody against *H. pylori*                                                      NS                                                                     44/93 (ESRD)                                                                                                                                                             55/93
  Tsukada *et al*. (2003)[@b30-gnl-13-628]                         Japan          Infected: 63±5, non-infected: 69±2                                                                                                                                                                                           Case-control                                 Immunochemically with a rabbit anti-*H. pylori* antibody                              Infected: 592±176 times, non-infected: 483±92 times                    9/36 (HD)                                                                                                                                                                44/81
  Misra *et al*. (2004)[@b31-gnl-13-628]                           India          CKD: 38.5±13.2, control: 37.9±11.15                                                                                                                                                                                          Case-control                                 Histology (H&E, alcian blue-periodic acid Schiff's, Loeffler's methylene blue)        NS                                                                     20/34 (CKD)                                                                                                                                                              41/50
  Al-Mueilo (2004)[@b64-gnl-13-628]                                Saudi Arabia   HD: 42.4±18.8 (16--85), control: 38.9±13.3                                                                                                                                                                                   Case-control                                 Histology                                                                             17±12.3 (3--48)                                                        34/54 (HD)                                                                                                                                                               38/60
  Nakajima *et al*. (2004)[@b32-gnl-13-628]                        Japan          CKD: 67.7±10.3, dialysis: 63.2±11.5, control: 62.8±11.7 (age-matched control)                                                                                                                                                Case-control                                 IgG antibody against *H. pylori*                                                      57.3±61.7                                                              16/30 (CKD without dialysis), 51/138 (dialysis)                                                                                                                          86/138
  Blusiewicz *et al*. (2005)[@b52-gnl-13-628]                      Poland         HD: 50.8±2.9, control: 61.3±2.2                                                                                                                                                                                              Case-control                                 Urease test, histology                                                                At least 6 mo                                                          19/30 (HD)                                                                                                                                                               22/31
  Simunić *et al*. (2005)[@b53-gnl-13-628]                         Croatia        HD: 52.2±14.8 (19--77), CKD without dialysis: 56.6±14.0 (21--78), control: 54.6±14.1 (23--79)                                                                                                                                Prospective study                            Urease test, histology, culture, IgG antibody against *H. pylori*                     NS                                                                     24/51 (CKD without dialysis), 23/55 (HD)                                                                                                                                 37/63
  Nardone *et al*. (2005)[@b54-gnl-13-628]                         Italy          CKD: 52.4±10, control: 54±7                                                                                                                                                                                                  Prospective study                            Urease test, histology, urea breath test, stool antigen for *H. pylori*               NS                                                                     19/39 (CKD without dialysis), 7/11 (HD)                                                                                                                                  34/93
  Moriyama *et al*. (2006)[@b33-gnl-13-628]                        Japan          Membranous nephropathy: 54±12, control: 45±11 (age-matched control)                                                                                                                                                          Case-control                                 HM-CAP serological test                                                               NS                                                                     21/32 (membranous nephropathy)                                                                                                                                           108/243
  Khedmat *et al*. (2007)[@b65-gnl-13-628]                         Iran           CKD: 43.9±2.7, HD: 47.9±3.5, control: 45±2.3                                                                                                                                                                                 Case-control                                 Urease test                                                                           46.9±10.7                                                              47/71 (CKD), 46/73 (HD)                                                                                                                                                  106/305
  Stolic *et al*. (2008)[@b55-gnl-13-628]                          Serbia         CKD: 60.65±12.74, control: 53.4±11.2                                                                                                                                                                                         Prospective study                            Urease test, histology (H&E)                                                          NS                                                                     29/124                                                                                                                                                                   72/120
  Abdulrahman *et al*. (2008)[@b34-gnl-13-628]                     Saudi Arabia   ESRD: 46.4±15.7, control: 48.6±12.3 (age, sex-matched control)                                                                                                                                                               Prospective study                            Histology                                                                             CKD duration: 39±18.6                                                  16/40 (ESRD)                                                                                                                                                             33/44
  Gioè *et al*. (2008)[@b56-gnl-13-628]                            Italy          Range 42--85                                                                                                                                                                                                                 Case-control                                 Urease test, histology (Giemsa)                                                       NS                                                                     75/142 (HD)                                                                                                                                                              59/132
  Sugimoto *et al*. (2009)[@b35-gnl-13-628]                        Japan          HD: 58.8±0.4, control: 58.4±0.6                                                                                                                                                                                              Case-control                                 IgG antibody against *H. pylori*                                                      8.4±0.3 yr                                                             262/539 (HD)                                                                                                                                                             314/400
  Asl and Nasri (2009)[@b66-gnl-13-628]                            Iran           HD: 56±14, control: 47±15                                                                                                                                                                                                    Cross-sectional                              Histology (Giemsa)                                                                    At least 6 mo                                                          23/40 (HD)                                                                                                                                                               13/40
  Chang *et al*. (2010)[@b36-gnl-13-628]                           Korea          HD: 62.0±9.8, control: 60.2±7.7                                                                                                                                                                                              Case-control                                 Urease test, histology (H&E, Wright stain)                                            *H. pylori* infected: 56.8±26.9, *H. pylori* non-infected: 66.4±26.1   12/33 (HD)                                                                                                                                                               36/55
  Chang and Hu (2014)[@b37-gnl-13-628]                             Taiwan         NS                                                                                                                                                                                                                           Retrospective cohort study                   Urease test, histology                                                                NS                                                                     261/446 (CKD), 81/144 (ESRD), ESRD vs control (OR, 0.54; 95% CI, 0.38--0.77), CKD vs control (OR, 0.64; 95% CI, 0.51--0.81)[\*](#tfn3-gnl-13-628){ref-type="table-fn"}   1,658/2,360
  Bunchorntavakul and Atsawarungruangkit (2014)[@b38-gnl-13-628]   Thailand       ESRD: median 38.7 (15.9--65), 39.4±10.3 (sex and age-matched control)                                                                                                                                                        Retrospective and prospective cohort study   Urease test, histology (H&E)                                                          Median 2.1 yr (0.2--15.3 yr)                                           29/107                                                                                                                                                                   41/105
  Zhu *et al*. (2016)[@b39-gnl-13-628]                             China          IgA nephropathy: 33.25±9.67 (serum IgG antibody against *H. pylori* positive), 33.30±14.05 (negative), non-IgA nephropathy: 34.50±13.96 (positive), 36.53±11.48 (negative), control: 38.96±9.22 (age, sex-matched control)   Case-control                                 ^14^C urea breath test                                                                NS                                                                     12/42 (IgA and non-IgA nephropathy)                                                                                                                                      10/30
  Can *et al*. (2017)[@b67-gnl-13-628]                             Turkey         Uremia patients: 69.5±13.8, non-uremic patients: 69±13.6                                                                                                                                                                     Case-control                                 Unknown                                                                               77.4±64.6 (patients with uremic GI bleeding, HD)                       11/51 (uremic GI bleeding)                                                                                                                                               31/101 (non-uremic GI bleeding)
  Kong *et al*. (2017)[@b40-gnl-13-628]                            China          48.6±14.3 (18--92) (total 22,044 patients with health checkup, 604 CKD patients were included)                                                                                                                               Cross-sectional                              IgG antibody against *H. pylori*                                                      NS                                                                     CKD vs. control (OR, 0.92; 95% CI, 0.75--1.12)[†](#tfn4-gnl-13-628){ref-type="table-fn"}                                                                                 \-

*Helicobacter pylori*, *H. pylori*; CKD, chronic kidney disease; ESRD, end-stage renal disease; IgG, immunoglobulin G; NS, no significant; HD, hemodialysis; PD, peritoneal dialysis; OR, odds ratio; CI, confidence interval; GI, gastrointestinal.

Adjusted for age, sex, peptic ulcer history, steroid or medication use, diabetes, hypertension, chronic heart failure, coronary artery disease, liver cirrhosis;

Adjusted for sex, age, hypertension, diabetes, body mass index, uric acid, smoking, drinking, total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol.

###### 

Results of Meta-Regression Analyses

  Model     Modifier                     Coefficient            Standard error   p-value
  --------- ---------------------------- ---------------------- ---------------- -----------------------
  Model 1   ESRD on dialysis vs CKD      −0.35                  0.49             0.48
            Ethnicity                    Asian: −0.62           0.76             0.41
                                         Middle Eastern: 0.10   0.80             0.90
                                         South American: 0.23   0.99             0.82
                                         Western: −0.14         0.79             0.86
                                                                                 0.09 (Q: 8.00, df: 4)
            HD or not                    HD: 0.06               0.34             0.86
                                         No HD: −0.01           0.47             0.98
                                                                                 0.98 (Q: 0.04, df: 2)
            Methodological quality       0.11                   0.34             0.74
  Model 2   ESRD on dialysis vs CKD      −0.34                  0.48             0.47
            Ethnicity                    Asian: −0.52           0.69             0.45
                                         Middle Eastern: 0.19   0.71             0.79
                                         South American: 0.34   0.89             0.70
                                         Western: −0.04         0.70             0.95
                                                                                 0.10 (Q: 7.76, df: 4)
            HD or not                    HD: 0.12               0.31             0.71
                                         No HD: −0.001          0.45             0.99
                                                                                 0.93 (Q: 0.14, df: 2)
            Dialysis more than 4 years   −0.17                  0.34             0.63
  Model 3   ESRD on dialysis vs CKD      −0.17                  0.50             0.23
            HD or not                    HD: 0.17               0.33             0.60
                                         No HD: 0.15            0.51             0.77
                                                                                 0.87 (Q: 0.29, df: 2)
            Methodological quality       0.23                   0.34             0.51

ESRD, end-stage renal disease; CKD, chronic kidney disease; HD, hemodialysis; df, degrees of freedom.
